Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportMolecular Targeting Probes - Radioactive and Nonradioactive

Radiosynthesis of 64Cu-labelled cetuximab for clinical use

Natsuki Honda, Hiroaki Kurihara, Kazuhiro Takahashi, Shusaku Tazawa, Kenji Tamura, Riyo Zochi, Yoko Morimoto, Yasuyoshi Watanabe and Yasuhiro Fujiwara
Journal of Nuclear Medicine May 2013, 54 (supplement 2) 1193;
Natsuki Honda
1National Cancer Center, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroaki Kurihara
1National Cancer Center, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kazuhiro Takahashi
2RIKEN CMIS, Kobe, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shusaku Tazawa
2RIKEN CMIS, Kobe, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenji Tamura
1National Cancer Center, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Riyo Zochi
2RIKEN CMIS, Kobe, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoko Morimoto
2RIKEN CMIS, Kobe, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yasuyoshi Watanabe
2RIKEN CMIS, Kobe, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yasuhiro Fujiwara
1National Cancer Center, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1193

Objectives Cetuximab, a chimeric human-mouse monoclonal antibody against epidermal growth factor receptor (EGFR), shows anti-tumor effects by binding EGFR and inhibiting proliferation of tumor cells. We have optimized the synthesis condition of radiolabelled antibody for clinical use, and demonstrated 64Cu-labeled trastuzumab PET imaging in the patients with breast cancer at SNMMI 2012 annual meeting. In this presentation, we demonstrate the synthesis of 64Cu-labelled cetuximab and its quality evaluation for clinical use.

Methods The 64Ni (p, n) 64Cu nuclear reaction was performed with 12 MeV proton irradiation for 2 h using a small medical cyclotron. The produced 64Cu was purified by anion-exchange resin to be 64CuCl2 solution. Cetuximab IgG (Erbitax®) was added to tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) mono N-hydroxysuccinimide ester dissolved in water. After 3 h, crude DOTA-cetuximab was purified by PD-10 column, and phosphate buffered saline (PBS) buffer including DOTA-cetuximab was exchanged for sodium acetate buffer by filtration. The purified 64CuCl2 solution was added with DOTA-cetuximab in acetic acid buffer and conjugated for 1 h. After the reaction, 64Cu-DOTA-cetuximab was filtered through a 0.22 μm filter in a sterile vial. The product was checked the physiological and chemical quality including specific activity, and examined the affinity to ErbB1 protein. All procedures were carried out under laminar air flow (Class 100 air).

Results 64Cu-DOTA-cetuximab injections passed quality control testing against specifications: radioactivity (>150 MBq), volume (4-6 mL), half-time (12.4-13.0 h), clarity (clear) and color (none), pH (5.0-8.0), radiochemical purity (>95 %), protein abundance (<100 μg), specific activity (>100 GBq/μmol), ErbB1 immunoreactivity (< Kd: 1 nM), sterility (Japanese Pharmacopoeia), and endotoxin (< 0.25 EU/mL).

Conclusions 64Cu-DOTA cetuximab injections synthesized by our procedure passed all of quality control testing for clinical use.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 54, Issue supplement 2
May 2013
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Radiosynthesis of 64Cu-labelled cetuximab for clinical use
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Radiosynthesis of 64Cu-labelled cetuximab for clinical use
Natsuki Honda, Hiroaki Kurihara, Kazuhiro Takahashi, Shusaku Tazawa, Kenji Tamura, Riyo Zochi, Yoko Morimoto, Yasuyoshi Watanabe, Yasuhiro Fujiwara
Journal of Nuclear Medicine May 2013, 54 (supplement 2) 1193;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Radiosynthesis of 64Cu-labelled cetuximab for clinical use
Natsuki Honda, Hiroaki Kurihara, Kazuhiro Takahashi, Shusaku Tazawa, Kenji Tamura, Riyo Zochi, Yoko Morimoto, Yasuyoshi Watanabe, Yasuhiro Fujiwara
Journal of Nuclear Medicine May 2013, 54 (supplement 2) 1193;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Molecular Targeting Probes - Radioactive and Nonradioactive

  • Clinical routine production of 177Lu-BPAMD
  • Production of Cu-64 using a solution target
  • Fully automated preparation of radiolabeled peptides in self-shielded radiosynthesis box
Show more Molecular Targeting Probes - Radioactive and Nonradioactive

Special MTA: Radiopharmacy Posters

  • Preclinical and a first-in man studies on [11C]CB184 for imaging 18 kDa translocator protein by positron emission tomography
  • Synthesis of [18F]Tetrafluoroborate ([18F]TFB) via Radiofluorination of Boron Trifluoride and Evaluation in a Murine C6-Glioma Tumor Model
  • 18F-Sulforhodamine 101 derivative as a potential agent for astrocytosis diagnosis: labelling and preliminary biological studies
Show more Special MTA: Radiopharmacy Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire